Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR2 | P21802 | 4/20 | 0.65 |
| ▸ | PDGFRA | P16234 | 3/20 | 0.61 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.61 |
| ▸ | KDR | P35968 | 2/20 | 0.56 |
| ▸ | EGFR | P00533 | 1/20 | 0.55 |
| ▸ | KIT | P10721 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7482948 | 0.83 | FGFR2 (0.61) | FGFR2PDGFRAPDGFRBKDREGFR | |
| SCHEMBL167396 | 0.82 | PDGFRA (0.74) | FGFR2PDGFRAPDGFRBKDREGFR | |
| SCHEMBL38659522 | 0.82 | FGFR2 (0.54) | FGFR2PDGFRAPDGFRBEGFR | |
| SCHEMBL31060325 | 0.82 | FGFR2 (0.78) | FGFR2PDGFRAPDGFRBKDREGFR | |
| SCHEMBL17117826 | 0.82 | FGFR2 (0.78) | FGFR2PDGFRAPDGFRBKDREGFR | |
| Hydrochloric Acid SCHEMBL23528156 | 0.81 | PDGFRA (0.72) | FGFR2PDGFRAPDGFRBKDREGFR | |
| SCHEMBL7481439 | 0.81 | SRC (0.60) | FGFR2PDGFRAPDGFRBKDREGFR | |
| SCHEMBL4365396 | 0.81 | PDGFRB (0.76) | FGFR2PDGFRAPDGFRBKDREGFR | |
| SCHEMBL7486400 | 0.80 | FGFR2 (0.84) | FGFR2PDGFRAPDGFRBKDREGFR | |
| SCHEMBL168048 | 0.80 | PDGFRB (0.79) | FGFR2PDGFRAPDGFRBKDREGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2892532-A1 | INHIBITORS OF MET, VEGFR AND RET FOR USE IN THE TREATMENT OF LUNG ADENOCARCINOMA | Exelixis, Inc. (US) | 2015-07-15 | — | — | EP | disclosed |
| EP-2844254-A1 | A DUAL MET - VEGF MODULATOR FOR TREATING OSTEOLYTIC BONE METASTASES | Exelixis, Inc. (US) | 2015-03-11 | — | — | EP | disclosed |
| WO-2014039971-A1 | INHIBITORS OF MET, VEGFR AND RET FOR USE IN THE TREATMENT OF LUNG ADENOCARCINOMA | EXELIXIS, INC. (US) | 2014-03-13 | — | — | WO | disclosed |
| WO-2013166296-A1 | A DUAL MET - VEGF MODULATOR FOR TREATING OSTEOLYTIC BONE METASTASES | EXELIXIS, INC. (US) | 2013-11-07 | — | — | WO | disclosed |
| EP-2621481-A1 | DUAL INHIBITORS OF MET AND VEGF FOR THE TREATMENT OF CASTRATION- RESISTANT PROSTATE CANCER AND OSTEOBLASTIC BONE METASTASES | Exelixis, Inc. (US) | 2013-08-07 | — | — | EP | disclosed |
| WO-2012044572-A1 | DUAL INHIBITORS OF MET AND VEGF FOR THE TREATMENT OF CASTRATION- RESISTANT PROSTATE CANCER AND OSTEOBLASTIC BONE METASTASES | EXELIXIS, INC. (US) | 2012-04-05 | — | — | WO | disclosed |